DRKS00009733已完成3 期
Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial - ALCAT
Klinikum der Universität München, Campus Großhadern0 个研究点目标入组 108 人开始时间: 2016年1月15日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Subjects will only be included in the study if they meet all of the following criteria:
- •Clinically confirmed cerebellar ataxia (CA) with a total SARA-Score = 3 (range 0-40) of hereditary or non-hereditary degenerative type
- •Patient did not receive any of the following prohibited medication within 4 weeks prior to randomization:
- •oAminopyridines (including substained-release form)
- •oAcetyl-DL-Leucine
- •oGabapentin
- •oVarenicline
- •oChlorzoxazone
- •The ability to follow study instructions and likely to attend and complete all required visits
- •Written informed consent of the subject prior to any study specific intervention
- •Age = 18 years
排除标准
- •Subjects will not be included in the study if any of the following criteria applies:
- •Subject is not able to give consent
- •Onset of ataxia in association with stroke, encephalitis, sepsis, hyperthermia or heat stroke
- •Toxic causes for ataxia of cerebellar type
- •Rapid progression of ataxia (development of severe ataxia in less than 12 weeks)
- •Subject suffers from any of the following:
- •ochronic diarrhea
- •ounexplained visual loss
- •omalignancies
- •oinsulin-dependent diabetes mellitus
- •Ataxia due to multiple sclerosis, ischemia, hemorrhage or tumor of the posterior fossa as confirmed by imaging
- •Ataxia due to clinical likely multisystem atrophy type C (MSA-C)
- •Diagnosis of clinical likely Friedreich ataxia
- •Known history of hypersensitivity to the investigational drug or derivates
- •Liver failure defined as AST/ALT > 300 U/l
- •Simultaneous participation in another clinical trial or participation in any clinical trial involving administration of an investigational medical product within 30 days prior to the beginning of the clinical trial
- •Subjects with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial
- •Known or persistent abuse of medication, drugs or alcohol
- •Females of childbearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration as listed in the patient informed consent form
- •Current or planned pregnancy or nursing women
- •Patients has received any of the following prohibited medication within 4 weeks prior to randomization
- •oAminopyridines (including substained-release form)
- •oAcetyl-DL-Leucine
- •oGabapentin
- •oVarenicline
- •oChlorzoxazone
- •After a wash-out period of at least 4 weeks these patients can be included in the study.
研究者
相似试验
进行中（未招募）
1 期
Effects of Acetyl-DL-Leucine on cerebellar ataxiaEUCTR2015-000460-34-DEHospital of the University of Munich108
进行中（未招募）
1 期
Effects of Acetyl-DL-Leucine on cerebellar ataxiaCerebellar ataxia is a form of ataxia originating in the cerebellum and is most often caused by neurodegenerative disorders of the cerebellum, either hereditary or sporadic. The leading clinical symptoms of cerebellar ataxia are disturbances of stance/gait (> 85%) with recurrent falls, limb ataxia with severe functional impairment of arm and hand movements, dysarthrophonia with impaired oral communication abilities and ocular motor disturbances with impaired vision.EUCTR2015-000460-34-ATHospital of the University of Munich108
招募中
2 期
Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multi-center, open-label, rater-blinded Phase II studyATAXIA TELANGIECTASIAG11.3Cerebellar ataxia with defective DNA repairDRKS00020511IntraBio Ltd30
进行中（未招募）
1 期
A safety and efficacy study of N-Acetyl-L-Leucine on Ataxia-TelangiectasiaTo demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning, and quality of life in patients with Ataxia-Telangiectasia (A-T)EUCTR2018-004407-39-GBIntraBio Ltd.39
进行中（未招募）
1 期
A safety and efficacy study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia.Ataxia-Telangiectasia (A-T)MedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-004407-39-DEIntraBio Ltd39